Atopic dermatitis (AD) represents the most common skin disease characterized by
heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic …

Treatable traits is a personalised medicine approach to the management of airway disease.
Assessing traits within the three domains of pulmonary, extra pulmonary and …

Background Atopic dermatitis (AD) is the leading cause of the global burden from skin
disease; no study has provided global and country-specific epidemiological estimates of AD …

Background Nemolizumab, an interleukin (IL)-31 receptor subunit α antagonist, inhibits the
IL-31 pathway of itch and skin inflammation in atopic dermatitis. Two international phase 3 …

Abstract The International Society of AD (ISAD) organized a roundtable on global aspects of
AD at the WCD 2023 in Singapore. According to the Global Burden of Disease (GBD) …

Atopic dermatitis (AD) is an inflammatory skin condition that frequently develops before the
onset of allergic rhinitis or asthma. More than 10% of children are affected by this serious …

Atopic dermatitis (AD) is a chronic inflammatory skin condition that affects individuals of all
age groups, manifesting as a spectrum of symptoms varying from mild to severe. Allergen …

Background Ruxolitinib cream is the first topical Janus kinase (JAK) inhibitor approved in the
United States (US) for the treatment of mild to moderate atopic dermatitis and nonsegmental …

Background Abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, improved itch
severity, sleep, and work productivity versus placebo in patients with moderate-to-severe …

The Staphylococcus sp. are a dominant part of the human skin microbiome and present
across the body. Staphylococcus epidermidis is a ubiquitous skin commensal, while S …